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The cancer stem cell hypothesis is becoming more widely accepted as a model for carcinogenesis. Tumours are heterogeneous
both at the molecular and cellular level, containing a small population of cells that possess highly tumourigenic “stem-cell”
properties. Cancer stem cells (CSCs), or tumour-initiating cells, have the ability to self-renew, generate xenografts reminiscent
of the primary tumour that they were derived from, and are chemoresistant. The characterisation of the CSC population within
a tumour that drives its growth could provide novel target therapeutics against these cells speciﬁcally, eradicating the cancer
completely. There have been several reports describing the isolation of putative cancer stem cell populations in several cancers;
however,nodeﬁnedsetofmarkershasbeenidentiﬁedthatconclusivelycharacterises“stem-like”cancercells.Thispaperhighlights
the current experimental approaches that have been used in the ﬁeld and discusses their limitations, with speciﬁc emphasis on the
identiﬁcation and characterisation of the CSC population in epithelial ovarian cancer.
1.Introduction
Ovarian cancer (OC) is the sixth most lethal malignancy
in women in the western world. Over 90% of malignant
tumoursareepithelial.Ithasbeenhypothesisedthattumours
can arise either from a single layer of cells covering the ovary
(the ovarian surface epithelium or OSE) or from the epithe-
lial lining of the ﬁmbrial end of the fallopian tube [1]. The
aetiology of OC remains poorly understood. One proposed
modelistheincessantovulationhypothesis,whichpostulates
that continuous rupture of the OSE during ovulation and
subsequentcellproliferationleadingtorepairmakeOSEcells
more susceptible to malignant transformation.
Approximately 70% of patients diagnosed with ovarian
cancer have advanced stage disease, partly because symp-
toms are vague and can be confused with gastrointestinal
complaints (e.g., bloating, constipation and mild abdominal
pain) [2, 3]. Despite improvements in debulking surgery and
initial good responses to platinum-based chemotherapies,
survival rates for the disease remain poor due to the devel-
opment of chemoresistant disease, and less than 60% of
cases survive more than 5 years. Thus, the identiﬁcation
of molecular markers that target chemoresistance may
represent suitable targets for new therapeutic approaches for
epithelial ovarian cancers (EOC).
The mechanisms underlying chemoresistance in cancer
are not clear. One hypothesis is that cancers are driven by
asubsetofhighlytumourigeniccellswithstemcellproperties
within the tumour, cancer stem cells (CSCs). The term CSC
is not meant to suggest that these cells have any association
with adult tissue stem cells; more recently, the term cancer
or tumour initiating cells (CIC or TIC) has come to be
thought of as more appropriate. As the term CSC is most
commonly used in the literature to describe these cells, for
the purpose of this paper, tumourigenic cancer cells with
stem cell properties will be referred to as CSC. According
to this model, only the CSCs, but not the remaining cells in
the tumour, can propagate tumourigenesis. CSCs have been
implicated in tumour initiation, progression, metastasis, and
drug resistance.
2. Cancer Stem Cells
A recent AACR workshop deﬁned the CSC as a malignant
cancer cell with a stem cell phenotype [4]. Whilst the CSC
hypothesis does not speciﬁcally address the mechanisms of2 Journal of Oncology
malignant transformation, it has been suggested that CSCs
are the malignant counterparts of normal adult tissue stem
cells, which, due to dysregulated signalling pathways, are
unable to maintain stem cell homeostasis. As is the case with
tissue stem cells, CSCs are thought to reside at the top of the
lineage hierarchy and give rise to diﬀerentiated cells, which
themselves have no potential for self-renewal, and therefore
do not contribute signiﬁcantly to tumour growth.
The idea that tissue stem cells are the underlying cells for
carcinogenesis is attractive. Due to their long lifespan, stem
c e l l sr e m a i ni nat i s s u ef o rl o n g e rp e r i o d so ft i m ec o m p a r e d
to their diﬀerentiated progeny, thereby making them more
likely to acquire transforming mutations. Additionally, it is
generally accepted that stem cells are more resistant to
apoptosis and DNA damage and are therefore more likely to
survive any insults [5, 6]. Whilst being quiescent in normal
tissue, stem cells are able to maintain the stem cell pool by
undergoing asymmetric cell division during processes such
as tissue damage. During this process, a stem cell divides
asymmetrically to generate an identical daughter cell (i.e.,
another stem cell) that is committed to diﬀerentiation. Adult
s t e mc e l lc a ng i v er i s et oaw i d er a n g eo fd i ﬀerentiated cells
and it has been suggested that CSCs undergo asymmetric cell
division to generate the diﬀerent cell types within a tumour,
thereby contributing to tumour heterogeneity often seen in
many cancers. The stem cell pool is also tightly regulated by
signalling pathways from the microenvironment of the stem
cellniche,andseveralofthesepathways,includingHedgehog
[7], and Wnt [8], have been implicated in carcinogenesis.
The CSC hypothesis suggests a paradigm shift in the
understanding of carcinogenesis and tumour cell biology.
This may have fundamental implications in therapeutic
interventions, including an explanation for the development
of chemoresistance. A role for CSCs in propagating and
maintaining metastasis has been proposed [9, 10]. Many
features of tumours can be explained by the inherent char-
acteristics of stem cells; for example, tumours selfrenew and
heterogeneity can be attributed to multilineage diﬀerentia-
tion. Dontu et al. [11] have proposed that breast cancers
may arise from mammary stem cells, or early progenitor
cells. It has also been shown that hypermethylation at
Polycomb promoter regions lock stem cells in a state of
self-renewal, which can lead to aberrant clonal expansion,
thus leading to cancer predisposition [12]. Even so, the
contrasting hypothesis that the dediﬀerentiation of mature
cells to a more pluripotent state as a potential mechanism
for the development of stem cell-like features by cancer cells
cannot be dismissed.
Cancercellswithstemcellpropertieshavebeenidentiﬁed
in acute myeloid leukemia and several solid malignancies
(Table 1).Whilstthefactthattissuestemcellsarethetargetof
transformationmaybetrueforcertainmalignancies,thishas
yet to be proven as a universal mechanism of tumorigenesis.
Consequently, the terms cancer and tumour-initiating cells
are thought to be more appropriate as they deﬁne cells with
tumour-initiating potential, without any reference to an
origin from tissue stem cells.
The ﬁrst strong evidence for the existence of cancer stem
cells in human tumours came from a study in acute myeloid
leukemia [13], in which the population of CD34+CD38−
cells isolated and transplanted into SCID mice formed
tumours that had similar features to human leukemia,
whilst populations containing cells with diﬀerent cell surface
marker proﬁles did not. Since then, several studies have
characterised the CSC in other types of tumours (Table 1).
Classically, stem cells are deﬁned by their two main char-
acteristics: self-renewal and pluripotency. And so by infer-
ence, to be classiﬁed as a CSC, a cell must meet the following
criteria: (i) the ability of self-renewal and diﬀerentiation into
diﬀerent cell types, (ii) the ability to propagate tumours
in vivo, (iii) the expression of distinct markers that permit
consistent isolation, and (iv) restriction to a minority of the
cell population (although this latter is now debatable, due to
recent evidence showing that the microenvironment of mice
alters the tumour-forming eﬃciency of engrafted cells) [14].
Table 1 summarises the various techniques and experi-
mentalapproachesthathavebeen usedto isolatetheputative
CSC component from primary tumours. The approaches
used rely on the intrinsic and functional properties of stem
cells. The most commonly used approach is the tumour
sphere assay, which evaluates the ability of cells to grow
as nonadherent spheroids under non-diﬀerentiating con-
ditions, and cell surface antigen proﬁle of subpopulations
found within tumours. The dye exclusion assay enables the
isolation of a side population of cells that extrude lipophilic
dyes due to the overexpression of drug eﬄux pumps; the
enzyme aldehyde dehydrogenase 1 is thought to be prefer-
entially active in stem-like cells. The tumourigenicity of the
putativeCSCcomponentisthenveriﬁedbyengraftmentinto
immunosuppressed mice. The aim is to show that a minimal
number of stem-like cells can give rise to tumours of the
same histopathology as the original primary tumours that
they have been isolated from.
2.1. Assaying Cancer Stem Cells
2.1.1. The Tumour Sphere Assay. Whilst there are no estab-
lished protocols for isolating pure populations of CSCs, the
general aim of many studies has been to enrich for cell
populations that show features that are characteristic of
normal stem cells, primarily the ability to self-renew and
diﬀerentiate into diﬀerent lineages. The tumourigenicity of
the isolated cell populations is then conﬁrmed by assessing
the tumour-forming potential of these cells in appropriate
mice models. A commonly used approach for CSC enrich-
ment is the tumour sphere assay, which evaluates the ability
of cancer cells to grow as multicellular spheroids under non-
diﬀerentiating and non-adherent conditions, a characteristic
believed to be indicative of self-renewal.
In a typical tumour sphere assay, cells from a primary
tumour or cancer cell line are dissociated into a single cell
suspension and cultured in a serum-free growth factor-
rich medium containing primarily epidermal growth factor
(EGF) and ﬁbroblast growth factor (FGF). Multicellular
spheroids of enriched CSCs that form can undergo serial
dissociationandpassagingtofurtherenrichforstemcell-like
cells.Journal of Oncology 3
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Although this is one of the most commonly used tech-
niques to evaluate self-renewal, the results from such assays
canbemisleading.Thecharacteristicofself-renewalcanonly
be inferred from the presence of tumour spheres in culture
if it can be shown that each tumour sphere has arisen from
a single cell under proliferative nonadherent conditions; yet,
there are few published studies that have actually demon-
strated this [38]. A detailed analysis of the methodologies
used in many studies shows that starting cell densities in
the tumour sphere assay are fairly high (e.g., 1000cells/mL).
These studies aim to utilise single cell suspensions, but the
high cell densities do not preclude the possibility that the
spheroids that form may have arisen from the aggregation
of mixed cell population and therefore would not be clonal.
Forneurospheres,ithasbeenshownthatspheroidsareclonal
only when cells are plated at low density [39].
2.1.2. Cell Surface Speciﬁc Antigen Proﬁle. Several studies
have prospectively isolated CSCs by looking for the presence
of extracellular markers that are thought to be stem cell-
speciﬁc. The markers most commonly used are CD133 and
CD44. CD133, a penta-membrane glycoprotein, has been
found to interact with cholesterol and may be involved
in maintaining membrane topology and membrane lipid
composition. Its expression has been shown to be restricted
to plasma membrane protrusions in epithelial cells [40]. It is
also thought to be a marker for neuroepithelial progenitor
cells and in haematopoietic progenitor cells. CD133 was
originally identiﬁed as a neural stem cell marker. It has been
used to characterise CSCs in brain tumours [17]a sw e l l
as several other cancers, including, prostate, colon, ovary,
and pancreas (Table 1). In breast cancer, CSCs have been
characterised as CD44+ and CD24− [41]. The limitation of
using cell surface marker expression to characterise CSCs is
that the approach requires prior knowledge of cell surface
markers that are expressed by the putative CSCs in the tissue
of interest, and often the choice of markers is inferred from
known expression of markers in normal adult stem cells.
Whilst CD133 and CD44 are thought to be indicative
of a CSC phenotype, it is not clear if they are universal
markers for characterising CSCs derived from all types of
tumours. Furthermore, the expression of CD133 and CD44
may not be restricted to the CSC population and may be
present in early progenitor cells. Their functions are largely
unknown, although there are reports implicating CD44 in
metastasis and chemoresistance. Recent evidence suggests
that CD133 is expressed in epithelial cells and may be
involved in maintaining pluripotency [40].
Epithelial-to-mesenchymal transition (EMT) is also
a feature of carcinogenesis, as cells acquire a more mesenchy-
mal phenotype during neoplastic transformation. A link
between CSC and EMT has been suggested, whereby trans-
formed human mammary epithelial cells that have under-
gone EMT show a gain of the CSC phenotype [42].
2.1.3. Hoechst 33342 Dye Exclusion Assay. Stem cells actively
eﬄux lipophilic compounds such as the ﬂuorescence dyes
Hoechst 33342 and rhodamine from their cytoplasm, as they
overexpressATP-bindingcassette(ABC)transporterproteins
on their cell surface, thus contributing to the intrinsic resis-
tance of stem cells to chemotherapy and radiotherapy. This
characteristic has been implicated in multidrug resistance in
cancers, as overexpression of multi-drug resistant proteins
enables cancer cells to remove chemotherapeutic drugs from
their cytoplasm.
Whenstainedwiththeﬂuorescentdyes,cellsoverexpress-
ing the ABC transporter proteins will eliminate the dye from
their cytoplasm, thus producing a lower signal than cells
not overexpressing ABC proteins. By combining ﬂuorescent
staining with ﬂuorescent-activated cell sorting (FACS) in
a cell population, a side population of cells (SP) can be
isolated that is enriched for stem “like” cells. As a control for
the SP phenotype, cells are stained in the presence of ABC
transporter inhibitors, which reverse the SP phenotype. The
most commonly used inhibitor is verapamil, which targets
P-glycoprotein encoded by the gene MDR1. A less frequently
used inhibitor is fumitremorgin C, which speciﬁcally targets
the BCRP transporter (encoded by ABCG2). Cells that retain
Hoechst are thought to contain terminally-diﬀerentiated
cells that are unable to self-renew; thus this is a marker
commonly used for identifying the non-SP fraction of a cell
population.
SP analysis, which was originally used to identify
haematopoietic stem cells from murine bone marrow [43],
has been used to isolate putative CSCs in several studies
in primary tumours and cell lines [19, 28, 29, 36, 44–50].
Reviewing the published literatures suggests that the per-
centage of SP cells that can be isolated from whole cell
line populations can range from 0%–20%. However, in the
majority of studies, the SP cells form a minority (<5%) of
the bulk cell population, supporting the idea that CSCs, like
stem cells, constitute a small proportion of cell cultures.
SP analysis provides a rapid method for isolating stem
cell-like cells; it relies on the functional characteristic of
stem cells and requires no prior knowledge of extracellular
markers. Nevertheless, the use of Hoechst as a method of
enrichingforCSChasreceivedcriticism.Ithasbeenreported
that Hoechst treatment reduces the clonogenicity of the
breast cancer cell line MCF7 and the ovarian cancer cell line
SKOV3 due to a loss in viability [51]. In this study, single
cells from unsorted cell populations, when grown in serum-
containing media under adherent conditions, generated
a clone that would satisfy the criteria for self-renewal.
Additionally, the same group reported that both SP and non-
SP cells generated clones in vitro and non-SP cells were able
to form both SP and non-SP cells, suggesting that non-SP
cells can self-renew as well.
2.1.4. Aldehyde Dehydrogenase Expression. More recently,
it has been suggested that an elevated level of aldehyde
dehydrogenase 1 (ALDH1) activity can select for stem-
like cells in both normal and malignant tissues. ALDH1 is
a detoxifying enzyme that is involved in the metabolism
of vitamin A to retinoic acid in the liver. It has been
suggestedthatretinoicacidsignallingisaprobableprotective
mechanism against oxidative damage in stem cells; recently,6 Journal of Oncology
levels of ALDH1 have been used as CSC markers in the
isolationofputativeCSC,andarethoughttobemorespeciﬁc
to the stem cell phenotype [10, 52–55]. In the colon, it
has been shown that the expressions of CD44 and CD133,
which have previously been used to isolate CSC populations,
are not restricted to the stem cell populations, which are
locatedatthebaseofcoloniccrypt,butalsotopopulationsof
rapidly proliferating cells located further up along the crypt.
The expression of ALDH1, however, is more limited to the
base of the crypt.
2.1.5. In Vivo Tumourigenicity Assays. Following the identi-
ﬁcation of the putative CSC population, cells are engrafted
into appropriate mice models to show that they are more
tumourigenic than their non-CSC counterparts. This is cur-
rently believed to be the gold-standard in the ﬁeld. Generally,
a small number of CSCs and non-CSCs are transplanted
into mice, and it is shown that CSCs have a higher tumour-
forming capacity than non-CSCs.
3. Cancer Stem Cells and Ovarian Cancer
Several characteristics of CSCs have been implicated in
chemoresistance and radiotherapy. Due to the overexpres-
sion of extracellular multi-drug transport proteins, CSCs are
able to eﬄux chemotherapeutic drugs from their cytoplasm.
Stem cells, and possibly CSCs, are inherently quiescent;
however, current drugs target rapidly cycling cells. Thus, the
hypothesis is that whilst the majority of cells in the bulk of
the tumour are eliminated, CSCs evade chemotherapy and
are able to reinitiate tumour development.
There is still uncertainty relating to the identiﬁcation
of CSCs in ovarian cancer. Several papers have described
the isolation of ovarian CSCs using diﬀerent approaches.
The ﬁrst study to be published identiﬁed clones established
from tumour ascites that were able to form anchorage-
independent spheroids and were shown to express the stem
cell markers Oct 3/4 and Nanog and the progenitor marker
Nestin [32]. Using ﬂow cytometry, Ferrandina et al. [34]
reported that two isoforms of CD133 (isoforms 1 and 2)
were both expressed in human ovarian tumours at a higher
frequency than in normal ovaries and metastatic omental
lesions [34]. Szotek et al. [50] used ﬂow cytometry to
isolate a side population of cells from genetically engineered
mouse ovarian cancer cell lines that expressed the multi-
drug transporter protein BCRP1 and were insensitive to
doxorubicin, suggesting a possible link between CSCs and
chemoresistance.Theyalsoisolatedasimilar,althoughmuch
smaller, side population of cells from the human ovarian
cancer cell lines IGROV-1, OVCAR3, and SKOV3, but these
SP cells were not further characterised.
Two other studies have independently deﬁned the ovar-
ian cancer stem cell by evaluating the CD44+CD117+ [37]
and CD133+ [31] phenotypes. The latter suggests an epige-
netic regulation of the CD133 promoter. Additionally, using
CD44, stem-like cells were enriched from patients’ samples
and were characterised by Myd88 expression and chemokine
and cytokine production [30]. Despite the diﬀerent proﬁles
described for CSCs by these studies, both studies reported
that the CSC phenotype was more resistant to platinum-
based therapy, which again, supports the idea that CSCs may
be responsible for chemoresistance.
Generally, these studies highlight the lack of consensus
about the molecular characteristics of ovarian CSCs. It is
likely that the expression of markers overlaps, and both
CD133 and CD44 characterise the ovarian CSC. Alterna-
tively, there may be more than one population of cells
with stem cell properties in ovarian cancers. The study by
Bapat et al. [32] postulated that stem cells are the target
of transformation in ovarian cancer, due to the fact that
a few of the clones isolated from ovarian cancer ascites
spontaneously immortalised in culture, suggesting a model
for disease development.
4. Issueswith the Current
ExperimentalApproaches
As described above, the experimental approaches used to
identify and characterise populations of putative CSC can be
classed in three major categories: (1) their isolation based on
the expression of extracellular markers, (2) their growth in
tumour sphere assays under non-diﬀerentiating conditions,
and(3)dyeexclusionduetotheoverexpressionofdrugeﬄux
pumps.Additionally,chemotherapeutictreatmentisthought
to enrich for CSCs; thus, when exposed to chemotherapy
drugs, CSCs are selected for [56]. It is not clear whether
chemoresistance is an inherent feature of CSCs or whether
they acquire this property throughout tumorigenesis.
Themostcommonapproachthathasbeenusedtoisolate
CSCs is to select for cells by the expression of extracellular
markers that may be associated with stemness. However,
the rationale underlying the selection of markers used for
this purpose is not always apparent. Although CD44 and
CD133 are the two most commonly used markers, it is
unclear whether or not they are ubiquitous. CD133 has
been extensively used to isolate CSCs in cancers of the brain
[18], prostate [57], pancreas [58], and ovary [31, 34]; but
whilst it has been successfully used to isolate brain tumour
stem cells, the use of CD133 in deﬁning CSCs in colon and
ovarian cancer has been more controversial. In the study by
Ferrandina et al., CD133 was suggested to be a marker for
ovarian cancer and was also used as an ovarian CSC marker
inthestudybyBabaetal.[31].Zhangetal.ontheotherhand
have suggested that CD44+CD117+ phenotype is indicative
of the ovarian CSC phenotype. In all of these studies, the
characteristics of the stem cell phenotype were conﬁrmed
by in vivo models and spheroid forming assays. It is likely
that both CD133 and CD44 are markers for stem cell-like
cells in epithelial OCs but there are no existing studies that
have compared the expression of CD44 and CD133 in EOCs.
It is possible that both markers are expressed by the same
populationofovarianCSC;alternatively,theymaybespeciﬁc
to diﬀerent populations of CSCs, or there may be other as yet
unidentiﬁedmarkersthatareubiquitousmarkersforovarian
CSCs. Several studies have shown that ovarian cancers are
extremely heterogeneous, and this may suggest that diﬀerentJournal of Oncology 7
populations of CSC can be responsible for tumourigenicity
in diﬀerent histological subtypes.
Another issue raised by the published literature is that
caution needs to be applied when interpreting the results
from tumour sphere assays. It is only possible to infer self-
renewal if it has conclusively been shown that multicellular
spheroidsarisefromsinglecells.Furthermore,itisimportant
to show that single cells isolated from such spheroids can
themselves generate spheroids through serial passaging.
Despite the amount of literature on CSCs, it is still not
clear as to what constitutes a universal CSC-speciﬁc proﬁle.
The deﬁnition of the CSC hypothesis is constantly evolving
to speciﬁcally address the mechanism of neoplastic transfor-
mationindiﬀerenttumourtypes.Itisbecomingincreasingly
evident that there may be more than one population of CSC
within a tumour. In addition, the cell of origin of CSCs
is not evident, as CSCs can arise from either stem cells or
progenitor cells. To be a true CSC, all the established criteria
that characterise the stem cell properties of a cancer cell need
to be satisﬁed.
5. Concluding Remarks
Ovarian cancer is a heterogeneous disease with histologically
deﬁned subtypes, and it is highly probable that CSCs
are involved in tumour development. Despite the number
of studies attempting to isolate ovarian CSCs, a well-
characterised proﬁle has not been established. It is essential
that further studies are carefully designed to address all
the functional characteristics of stem cells covering: (i) self-
renewal, where a single CSC is shown to form multicellular
spheroid in vitro and (ii) multilineage diﬀerentiation such
that only the putative CSC would divide asymmetrically to
generate several cell types. The tumourigenicity of these cells
t h e nn e e d st ob ev a l i d a t e di na na p p r o p r i a t ein vivo model
that is permissible to tumour formation. The development
of chemoresistant disease represents a major hindrance to
successful ovarian cancer treatment, and the identiﬁcation
of a molecular proﬁle of ovarian CSC may aid to the
development of more eﬀective targeted therapy.
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